Stock Fundamentals

Company Information

Company Name
Mereo BioPharma Group PLC ADR
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US5894921072
CUSIP: 589492107
Currency: USD
Full Time Employees: 39
Phone: 44 33 3023 7300
Fiscal Year End: December
IPO Date: Apr 24, 2019
Description:

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Address:

One Cavendish Place, London, United Kingdom, W1G 0QF

Directors & Officers

Name Title Year Born
Dr. Denise Vera Scots-Knight Ph.D. Co-Founder, CEO & Executive Director 1959
Mr. Charles Edward Sermon Co-Founder, General Counsel, Business Development & Company Secretary 1969
Ms. Christine Fox CPA Chief Financial Officer 1981
Dr. John A. Lewicki Ph.D. Chief Scientific Officer 1952
Ms. Bal Lally VP & Head of HR NA
Dr. Jackie Parkin Senior VP & Therapeutic Head 1958
Ms. Alexandra Hughes-Wilson Chief of Patient Access & Commercial Planning 1971
Mr. Bo Kara Senior VP and Head of Pharmaceutical Development & CMC NA
Ms. Bharti Navsariwala VP & Head of Regulatory Affairs NA
Dr. Ogun Sazova VP & Head of Medical Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 12, 2024 Charles Sermon N/A Sale 9.98K $4.47 $44.61K
Sep 12, 2024 Christine Ann Fox N/A Sale 9.13K $4.47 $40.80K
Sep 12, 2024 Denise Scots-Knight N/A Sale 28.61K $4.47 $127.89K
Sep 12, 2024 John A Lewicki N/A Sale 5.21K $4.47 $23.30K
Aug 22, 2024 Deepika Pakianathan N/A Sale 105.24K $4.43 $466.23K
Jun 25, 2024 Charles Sermon N/A Sale 14.20K $3.69 $52.41K
Jun 25, 2024 Christine Ann Fox N/A Sale 12.99K $3.69 $47.93K
Jun 25, 2024 Denise Scots-Knight N/A Sale 40.71K $3.69 $150.23K
Jun 25, 2024 John A Lewicki N/A Sale 7.42K $3.69 $27.37K
May 22, 2024 Alexandra Hughes-Wilson N/A Sale 100.43K $2.97 $298.28K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Rubric Capital Management LP 15.31M Mar 31, 2026 9.59% $0.05 0.00%
EcoR1 Capital, LLC 13.37M Mar 31, 2026 8.38% $0.19 70.16%
683 Capital Management LLC 12.00M Mar 31, 2026 7.52% $0.21 -20.13%
Bank of America Corp 8.20M Mar 31, 2026 5.13% $0.00 32,048.47%
Defilade Capital Management, L.P. 7.56M Mar 31, 2026 4.74% $0.35 0.00%
Newtyn Management LLC 7.08M Mar 31, 2026 4.44% $0.25 3,051.54%
Millennium Management LLC 3.56M Mar 31, 2026 2.23% $0.00 4,154.96%
Tejara Capital Ltd 2.04M Mar 31, 2026 1.28% $0.22 -5.66%
UBS Group AG 1.49M Mar 31, 2026 0.93% $0.00 -4.41%
Sontag Advisory LLC 796.04K Mar 31, 2026 0.50% $0.00 0.00%
Marshall Wace Asset Management Ltd 686.99K Mar 31, 2026 0.43% $0.00 0.00%
Group One Trading, LP 441.64K Dec 31, 2025 0.28% $0.00 223.33%
EntryPoint Capital LLC 400.70K Dec 31, 2025 0.25% $0.07 0.00%
BlackRock Inc 302.99K Mar 31, 2026 0.19% $0.00 -3.08%
Knott David M Jr 300.34K Mar 31, 2026 0.19% $0.06 0.00%
Two Sigma Advisers, LLC 251.90K Dec 31, 2025 0.16% $0.00 4.01%
Acadian Asset Management LLC 209.08K Mar 31, 2026 0.13% $0.00 0.00%
Susquehanna International Group, LLP 195.92K Mar 31, 2026 0.12% $0.00 0.00%
Two Sigma Investments LLC 187.84K Mar 31, 2026 0.12% $0.00 -64.23%
ADAR1 Capital Management LLC 150.00K Mar 31, 2026 0.09% $0.00 0.00%

Shares Statistics

Shares Outstanding: 159.62M
Shares Float: 114.47M
% Insiders: 95.90%
% Institutions: 4,790.50%
Short % Float: 6.29%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 International Biotechnology Ord 1.07M 0.67% ▲ 0.00% Feb 28, 2026
2 Truvalue Glb Phrmctl Blgcl Eq (QDII) A 992.10K 0.62% ▲ 0.00% Dec 31, 2025
3 HealthInvest Sustainable Healthcare E 358.90K 0.22% ▲ 0.00% Nov 30, 2025
4 iShares Genomics Immnlgy & Hlthcr ETF 259.52K 0.16% ▲ 0.00% May 29, 2026
5 HealthInvest S&M Cap Healthcare C 186.20K 0.12% ▲ 0.00% Nov 30, 2025
6 Virtus LifeSci Biotech Clinical Trls ETF 152.07K 0.10% ▲ 0.00% May 29, 2026
7 State Street® SPDR® S&P® Intl Sm Cp ETF 132.70K 0.08% ▲ 0.00% May 29, 2026
8 UBS Global Equity Biotech 128.03K 0.08% ▲ 0.00% Mar 31, 2026
9 Fidelity Nasdaq Composite Index 92.53K 0.06% ▲ 0.00% Apr 30, 2026
10 Forefront Tiresias Strategy 33.18K 0.02% ▲ 73.37% Sep 30, 2025

Valuation Metrics

Enterprise Value: $8.63M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $48.68M
EBITDA: $-35.58M
Book Value: $0.21
Earnings/Share: $-0.20
Profit Margin: 0.00%
Operating Margin: -7,242.20%
ROA (TTM): -41.55%
ROE (TTM): -75.87%
Revenue (TTM): $500.00K
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 10.46x 0.01x 0.11x -150.03x -0.01x
2024-12-31 5.40x 0.10x 0.20x -34.56x -0.15x
2023-12-31 6.72x 0.10x 0.24x -9.86x -0.19x
2022-12-31 3.09x 0.27x 0.34x -15.97x -0.35x
2021-12-31 7.92x 0.13x 0.30x -5.41x 0.60x
2020-12-31 3.47x -0.83x 1.24x -7.55x -0.08x
2019-12-31 1.02x 0.54x 0.53x -14.42x -0.65x
2018-12-31 2.13x 0.66x 0.51x -14.91x -0.62x
2017-12-31 6.57x 0.33x 0.35x -41.57x -0.47x
2016-12-31 18.94x 0.04x 0.09x -201.26x -0.08x
2015-12-31 28.85x 0.00x 0.05x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MREO.US!